My figure on Cabo/mCRPC market is higher than 800 patients per year.
According to NIH, 30,000 patients die on prostate cancer each year in US alone. Among these, almost all of them will end up bone mets with pain (greater than 90%). If the average survival is 2 years after diagnosis of mCRPC, this will translate to 60,000 mCRPC at any given time in US (world wide could add up to 150,000). If 50% of patients eventually receive Cabo for bone mets, this number could be 100X more (7-80,000). If pre-chemo combined with abi/other pan out, it could easily double to triple this 80,000 figure. If each patient stay on Cabo for 5 to 6 months, this CRPC market for Cabo can easily top 1B worldwide. It is huge!